Physical-Layer Communications Using Direct Antenna Modulation

Conventional wireless communications could be threatened by an eavesdropper with a sufficiently sensitive receiver and unlimited computational resources, or may reach the channel capacity in the near future. Recent research into a new digital modulation technique termed Direct Antenna Modulation (DAM) shows that DAM is a potential solution to the aforementioned problems. Direction-dependency, which describes the manner of signal transmission, is the most important attribute of a DAM system. Direction-dependent transmission can provide extra protection from a physical-layer source against security attack. Various transmission schemes are discussed in this work, and it is shown that accurate demodulation can be prevented from eavesdropping in the following two scenarios: first, when the angular separation between eavesdropper and intended recipient is very small; second, when one or two eavesdropping directions are pre-known. In addition, DAM system can be configured to have extra channel resources by introducing space as an additional domain for multiplexing. With the technique of space multiplexing, the transmitter can send independent data streams towards multiple receivers located at various transmission directions simultaneously. An algorithmic method is also presented to provide space multiplexing with a relatively low system cost

A Novel Heterogeneous Parallel System Architecture Based EtherCAT Hard Real-Time Master in High Performance Control System

EtherCAT is one of the preferred real-time Ethernet technologies. However, EtherCAT is not applicable in high-end control fields due to real-time constraints. Clock synchronization and cycle time are the most representative limitations. In this paper, a novel Heterogeneous Parallel System Architecture (HPSA) with features of parallel computation and hard real-time is presented. An HPSA-based EtherCAT hard real-time master is developed to significantly improve clock synchronization and shorten cycle time. Traditional EtherCAT masters feature serial processing and run on a PC. This HPSA-based master consists of two parts: EtherCAT master stack (EMS) and EtherCAT operating system (EOS). EMS implements the parallel operation of EtherCAT to realize the shorter cycle time, and EOS brings a hard real-time environment to the HPSA-based master to improve clock synchronization. Furthermore, this HPSA-based master operates on a heterogeneous System-on-a-chip (SoC). EMS and EOS form a heterogeneous architecture inside this SoC to achieve low-latency process scheduling. Experimental results show that in our HPSA-based EtherCAT hard real-time master, the cycle time reaches the sub-50 μs range, and the synchronization error reduces to several nanoseconds. Thus, this HPSA-based master has great application value in high-performance control systems

A Novel Heterogeneous Parallel System Architecture Based EtherCAT Hard Real-Time Master in High Performance Control System

EtherCAT is one of the preferred real-time Ethernet technologies. However, EtherCAT is not applicable in high-end control fields due to real-time constraints. Clock synchronization and cycle time are the most representative limitations. In this paper, a novel Heterogeneous Parallel System Architecture (HPSA) with features of parallel computation and hard real-time is presented. An HPSA-based EtherCAT hard real-time master is developed to significantly improve clock synchronization and shorten cycle time. Traditional EtherCAT masters feature serial processing and run on a PC. This HPSA-based master consists of two parts: EtherCAT master stack (EMS) and EtherCAT operating system (EOS). EMS implements the parallel operation of EtherCAT to realize the shorter cycle time, and EOS brings a hard real-time environment to the HPSA-based master to improve clock synchronization. Furthermore, this HPSA-based master operates on a heterogeneous System-on-a-chip (SoC). EMS and EOS form a heterogeneous architecture inside this SoC to achieve low-latency process scheduling. Experimental results show that in our HPSA-based EtherCAT hard real-time master, the cycle time reaches the sub-50 μs range, and the synchronization error reduces to several nanoseconds. Thus, this HPSA-based master has great application value in high-performance control systems

Predictive Analysis of Vehicular Lane Changes: An Integrated LSTM Approach

In the rapidly advancing domain of vehicular traffic management and autonomous driving, accurate lane change predictions are paramount for ensuring safety and optimizing traffic flow. This study introduces a comprehensive two-stage prediction model that harnesses the capabilities of long short-term memory (LSTM) for anticipating vehicular lane changes. Initially, we employed a variety of models, such as regression methods, SVMs, and a multilayer perceptron, to categorize lane change behaviors. The dataset was then segmented based on vehicle trajectories and lane change patterns. In the subsequent phase, we utilized the superior classification outcomes from LinearSVC to curate our training data. We developed two dedicated LSTM networks tailored to specific datasets: the lane-keeping LSTM (LK-LSTM) and the lane-changing LSTM (LC-LSTM). By integrating insights from both models, we achieved a comprehensive prediction of vehicular lane changes. Our results indicate that the unified prediction model markedly enhances prediction precision. Accurate lane change predictions offer valuable contributions to advanced driver-assistance systems (ADAS), with the potential to minimize traffic mishaps and enhance traffic fluidity. As we transition to a more autonomous automotive era, refining these predictions becomes essential in seamlessly merging human and automated driving experiences

Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta‐analysis

Abstract Background By prolonging overall survival and reducing disease recurrence rates, immune checkpoint inhibitors (ICIs) are an emerging adjuvant therapy option for patients with resectable malignant tumors. However, the safety profile (deaths and adverse events [AEs]) of adjuvant ICIs has not been fully described. Methods We searched the literature for phase III randomized clinical trials that compared PD‐1, PD‐L1, and CTLA‐4 inhibitors in solid malignant tumors. Incidences of death, discontinuation, AEs of any cause, treatment‐related adverse events (TRAEs), and immune‐related adverse events (IRAEs) were extracted for the network meta‐analysis. Network meta‐analyses with low incidence and poor convergence are reported as incidences with 95% confidence intervals (95% CIs). Results Ten randomized clinical trials that included 9243 patients who received ICI adjuvant therapy were eligible. In total, 21 deaths due to TRAEs were recorded, with an overall incidence of 0.40% (95% CI: 0.26–0.61). The treatment‐related mortality rates for ipilimumab (0.76%, 95% CI: 0.31–1.55) and atezolizumab (0.56%, 95% CI: 0.18–1.31) were higher than for pembrolizumab (0.24%, 95% CI: 0.10–0.56) and nivolumab (0.30%, 95% CI: 0.08–0.77). The most frequent causes of death were associated with the gastrointestinal (0.10%, 95% CI: 0.04–0.24) and pulmonary (0.08%, 95% CI: 0.03–0.21) systems. Compared with the control arm, we found that nivolumab (odds ratio [OR]: 2.73, 95% CI: 0.49–15.85) and atezolizumab (OR: 12.43, 95% CI: 2.42–78.48) caused the fewest grade ≥3 TRAEs and IRAEs. Commonly reported IRAEs of special interest were analyzed, and two agents were found to have IRAEs with incidences >10%, i.e., hepatitis for atezolizumab (14.80%, 95% CI: 12.53–17.32) and hypophysitis for ipilimumab (13.53%, 95% CI: 11.38–15.90). Conclusions Ipilimumab and atezolizumab were correlated with higher treatment‐related death rates than pembrolizumab and nivolumab, in which the gastrointestinal and pulmonary systems were mostly involved. Regarding severe TRAEs and IRAEs, nivolumab and atezolizumab are likely to be the safest agent, respectively. This study will guide clinical practice for ICI adjuvant therapies

Efficacy of Topical Compound Danxiong Granules for Treatment of Dermatologic Toxicities Induced by Targeted Anticancer Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial

Dermatologic toxicities resulting in dose reduction or discontinuation of treatment pose challenges for targeted anticancer therapies. We conducted this randomized, double-blind, placebo-controlled trial to investigate the efficacy of topical application of Compound Danxiong Granules (CDG) for treatment of dermatologic toxicities associated with targeted anticancer therapies. One hundred and ten patients with dermatologic toxicities induced by targeted anticancer therapies were randomly assigned to CDG or placebo group. Each crude herb (Rhizoma Chuanxiong, Paeonia suffruticosa Andr., Cortex Phellodendri, Geranium sibiricum L., and Flos Carthami) was prepared as an instant herbal powder. Application of the CDG via topical washes lasted 20 minutes, twice daily, for 10 days. The primary outcome was the total effective rate, defined as reduction in at least one grade of skin toxicity. The total effective rate was 77.61% (52/67) in the CDG group and 27.27% (9/33) in the placebo group (P<0.0001). Compared to the placebo treatment, CDG treatment achieved a higher total effective rate for hand-foot skin reaction (95.45% versus 27.27%), acneiform eruption (69.23% versus 30.78%), and paronychia (68.42% versus 22.22%). Topical application of CDG can effectively attenuate dermatologic toxicities induced by targeted anticancer therapies. The effect of CDG was more pronounced in hand-foot skin reaction